ANAHEIM, Calif., Aug. 2, 2023 /PRNewswire/ — Histologics LLC and its Founder and CEO, Dr. Neal Lonky have been nominated for the Orange County Business Journal Innovator of the Year award for 2023. The Kylon® medical fabric, a replacement for conventional steel metal tool devices has revolutionized cervical and wound biopsy, and gentle or surgical debridement for chronic wound care. Over 1M clinical cases have been performed with this safe, sterile, single use disposable technology in the United States thus far with stellar clinical outcomes.
Per the Orange County Business Journal:
“The 2023 Innovator of the Year Awards program allows for the recognition of five innovators who are changing the status quo in OC’s community of business. There are 51 nominees for the 2023 Innovator of the Year Awards. The 2023 Innovator of the Year Awards special report which features nominee profiles and specialized advertorials from our sponsors was published on July 31, 2023. Five awards will be presented at the 2023 Innovator of the Year Awards Luncheon & Program on September 7, 2023, at the Irvine Marriott. The 2023 IOTY Awards Keynote Speaker is Kurt Busch, Co-Founder & CEO of Syntiant Corp.”
For more information regarding Histologics, the Women’s Health or Wound Care Technologies, or Dr. Lonky’s background, please contact Lily Ramos at histologicswc@gmail.com, Toll Free: 888-235-2275. Please visit our websites at www.histologics.com and www.histologicswc.com for more information or if a medical professional, to request samples.
SOURCE Histologics LLC
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…